Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 953 participants.

Also called NCT02104804

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 953 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02104804
Other papers using this trial's data
  • Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial Diabetes, obesity & metabolism, 2018-04 DOI, PubMed 29144061

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02104804. Randomized; quadruple masking; primary purpose treatment. Start 2014-05-07 (actual); primary completion 2016-02-26 (actual). Results posted on 2017-10-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Saxagliptin 5mg
Intervention (Drug)
Placebo for Saxagliptin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02104804
Content hash
fd5c745a097c4103cf36337a7c877e27f881a51bd8c2177069499e611af6cb51